Preferential inhibition of xanthine oxidase by 2-amino-6-hydroxy-8- mercaptopurine and 2-amino-6-purine thiol

BMC Biochemistry

Volumn 8, Issue , 2007, Pages

  Kalra, Sukirti ^a   Jena, Gopabandhu ^a   Tikoo, Kulbhushan ^a   Mukhopadhyay, Anup Kumar ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 6 HYDROXY 8 MERCAPTOPURINE; 6 MERCAPTOPURINE DERIVATIVE; MERCAPTOPURINE; TIOGUANINE; UNCLASSIFIED DRUG; XANTHINE OXIDASE; 2-AMINO-6-HYDROXY-8-MERCAPTOPURINE; 2-AMINO-6-PURINETHIOL; 6 THIOURIC ACID; 6 THIOXANTHINE; 6-THIOURIC ACID; 6-THIOXANTHINE; ADENINE; DRUG DERIVATIVE; ENZYME INHIBITOR; URIC ACID; XANTHINE; XANTHINE DERIVATIVE;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG INHIBITION; DRUG STRUCTURE; HYDROXYLATION; IC 50; KINETICS; MALE; MOUSE; NONHUMAN; CHEMICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYME SPECIFICITY; METABOLISM;

MUS;

6-MERCAPTOPURINE; ADENINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HYDROXYLATION; KINETICS; MODELS, CHEMICAL; MOLECULAR STRUCTURE; SUBSTRATE SPECIFICITY; URIC ACID; XANTHINE; XANTHINE OXIDASE; XANTHINES;

EID: 34249895926     PISSN: None     EISSN: 14712091     Source Type: Journal    
DOI: 10.1186/1471-2091-8-8     Document Type: Article

References (55)

1. Intravenous mercaptopurine: life begins at 40. D Pinkel, J Clin Oncol 1993 11 1826 1831 8355049
2. Clinical evaluationof a new antimetabolite, 6-mercaptopurine in the treatment of leukemia and allied diseases. JH Burchenal ML Murphy RR Ellison MP Sykes TC Tan LA Leone DA Karnofsky LF Craver HW Dargeon CP Rhoads, Blood 1953 8 965 999 13105700
3. Azathioprine and 6-mercaptopurine alter the nucleotide balance in endothelial cells. G Weigel A Griesmacher RA DeAbreu E Wolner MM Mueller, Thromb Res 1999 94 87 94 10.1016/S0049-3848(98)00199-6 10230893
4. The clinical pharmacology of 6-mercaptopurine. L Lennard, Eur J Clin Pharmacol 1992 43 329 339 10.1007/BF02220605 1451710
5. Symposium on immunosuppressive drugs. Biochemistry and pharmacology of purine analogues. GB Elion, Fed Proc 1967 26 898 904 5337283
6. Potentiation by inhibition of drug degradation: 6-substituted purines and xanthine oxidase. GB Elion S Callahan H Nathan S Bieber RW Rundles GH Hitchings, Biochem Pharmacol 1963 12 85 93 10.1016/0006-2952(63)90012-1
7. Aminoimidazolylmethyluracil analogues as potent inhibitors of thymidine phosphorylase and their bioreductive nitroimidazolyl prodrugs. P Reigan PN Edwards A Gbaj C Cole ST Barry KM Page SE Ashton RW Luke KT Douglas IJ Stratford M Jaffar RA Bryce S Freeman, J Med Chem 2005 48 392 402 10.1021/jm049494r 15658853
8. Conversion of xanthine dehydrogenase to xanthine oxidase as a possible marker for hypoxia in tumours and normal tissues. RF Anderson KB Patel K Reghebi SA Hill, Br J Cancer 1989 60 193 197 2765364
9. Proceedings: Serum xanthine oxidase in hepatocellular damage. S Giler O Sperling S Brosh I Urca A De Vries, Isr J Med Sci 1975 11 1225 1205828
10. Xanthine oxidase levels in human brain tumors. E Kokoglu A Belce E Ozyurt Z Tepeler, Cancer Lett 1990 50 179 181 10.1016/0304-3835(90)90262-V 2322931
11. Metabolic and therapeutic effects of allopurinol in patients with leukemia and gout. WR Vogler JA Bain CM Huguley HG Palmer ME Lowrey, Am J Med 1966 40 548 559 10.1016/0002-9343(66)90118-5
12. Relationship between Metabolic Fates and Antitumor Activities of Thiopurines. GB Elion S Callahan RW Rundles GH Hitchings, Cancer Res 1963 23 1207 1217 14070377
13. The management of gout. BT Emmerson, N Engl J Med 1996 334 445 451 10.1056/NEJM199602153340707 8552148
14. Treatment of the gout and other forms of crystal-induced arthritis. GP Rodnan, Bull Rheum Dis 1982 32 43 53 6762236
15. On the mechanism of inactivation of xanthine oxidase by allopurinol and other pyrazolo[3,4-d]pyrimidines. V Massey H Komai G Palmer GB Elion, J Biol Chem 1970 245 2837 2844 5467924
16. The housekeeping gene xanthine oxidoreductase is necessary for milk fat droplet enveloping and secretion: gene sharing in the lactating mammary gland. C Vorbach A Scriven MR Capecchi, Genes Dev 2002 16 3223 3235 12502743 10.1101/gad.1032702
17. Flavoprotein structure and mechanism. 4. Xanthine oxidase and xanthine dehydrogenase. R Hille T Nishino, Faseb J 1995 9 995 1003 7649415
18. Crystal structures of bovine milk xanthine dehydrogenase and xanthine oxidase: structure-based mechanism of conversion. C Enroth BT Eger K Okamoto T Nishino T Nishino EF Pai, Proc Natl Acad Sci USA 2000 97 10723 10728 11005854 10.1073/pnas.97.20.10723
19. Drug therapy: immunosuppressive agents. SR Kaplan P Calabresi, N Engl J Med 1973 289 1234 1236 4594161
20. Azathioprine and allopurinol: a potentially dangerous combination. G Venkat Raman VL Sharman HA Lee, J Intern Med 1990 228 69 71 2384739
21. Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. S Zimm JM Collins D O'Neill BA Chabner DG Poplack, Clin Pharmacol Ther 1983 34 810 817 6580097
22. Effect of allopurinol (4-hydroxyprazolo(3,4-d)pyrimidine) on xanthine accumulation by milk xanthine oxidase in vitro. MM Jezewska, Eur J Biochem 1974 46 361 365 10.1111/j.1432-1033.1974.tb03628.x 4408204
23. Superoxide radical production by allopurinol and xanthine oxidase. C Galbusera P Orth D Fedida T Spector, Biochem Pharmacol 2006 71 1747 1752 10.1016/j.bcp.2006.02.008 16650385
24. Preferential inhibition of the plasma membrane NADH oxidase (NOX) activity by diphenyleneiodonium chloride with NADPH as donor. DJ Morre, Antioxi Redox Signal 2002 4 207 212 10.1089/152308602753625960
25. Human PC4 is a substrate-specific inhibitor of RNA polymerase II phosphorylation. LM Schang GJ Hwang BD Dynlacht DW Speicher A Bantly PA Schaffer A Shilatifard H Ge R Shiekhattar, J Biol Chem 2000 275 6071 6074 10.1074/jbc.275.9.6071 10692395
26. Synthesis and structure-activity relationships of 1-phenylpyrazoles as xanthine oxidase inhibitors. S Ishibuchi H Morimoto T Oe T Ikebe H Inoue A Fukunari M Kamezawa I Yamada Y Naka, Bioorg Med Chem Lett 2001 11 879 882 10.1016/S0960-894X(01)00093-2 11294382
27. Progress towards the discovery of xanthine oxidase inhibitors. F Borges E Fernandes F Roleira, Curr Med Chem 2002 9 195 217 11860355
28. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. K Okamoto BT Eger T Nishino S Kondo EF Pai T Nishino, J Biol Chem 2003 278 1848 1855 10.1074/jbc.M208307200 12421831
29. 6-(N-benzoylamino)purine as a novel and potent inhibitor of xanthine oxidase: inhibition mechanism and molecular modeling studies. H Tamta R Thilagavathi AK Chakraborti AK Mukhopadhyay, J Enzyme Inhib Med Chem 2005 20 317 324 10.1080/14756360500112326 16206825
30. Biochemical characterization of some Pyrazolopyrimidine-based inhibitors of xanthine oxidase. H Tamta S Kalra AK Mukhopadhyay, Biochemistry (Mosc) 2005 71 S49 S54
31. On the mechanism of inactivation of xanthine oxidase by allopurinol and other pyrazolo[3,4-d]pyrimidines. V Massey H Komai G Palmer GB Elion, J Biol Chem 1974 245 2837 2844
32. Mechanism of Inhibition of Xanthine oxidase with a new tight binding inhibitor. K Okamoto T Nishino, J Biol Chem 1995 270 7816 7821 10.1074/jbc.270.14.7816 7713871
33. Y-700 [1-[3-Cyano-4-(2,2-dimethylpropoxy)phenyl]-1H-pyrazole-4-carboxylic Acid]: A potent Xanthine oxidoreductase inhibitor with hepatic excretion. A Fukunari K Okamoto T Nishino BT Eger EF Pai M Kamezawa I Yamada N Kato, J Pharmacol Exp Ther 2004 311 519 528 10.1124/jpet.104.070433 15190124
34. +2 Ion. AK Sau MS Mondal, J Chem Soc Chem Comm 1994 13 1547 1548 10.1039/c39940001547
35. Accurate prediction of xanthine oxidase inhibition based on the structure of flavonoids. DECV Hoorn RJ Nijveldt PAMV Leeuwen Z Hofman LM Rabbet DBAde Bont KV Norren, Eur J Pharmacol 2002 451 111 118 10.1016/S0014-2999(02)02192-1 12231379
36. Crystal structures of bovine milk xanthine dehydrogenase and xanthine oxidase: Structure-based mechanism of conversion. C Enroth BT Eger K Okamoto T Nishino T Nishino EF Pai, Proc Nat Acad Sci USA 2000 97 10723 10728 11005854 10.1073/pnas.97.20.10723
37. Thecrystal structure of xanthine oxidoreducatse during catalysis: Implicationsfor reaction mechanism and enzyme inhibition. K Okamoto K Masumoto R Hille BT Eger EF Pai T Nishino, Proc Nat Acad Sci USA 2004 101 7931 7936 15148401 10.1073/pnas.0400973101
38. Cooperative catalysis in the homodimer subunits of xanthine oxidase. LA Tai KC Hwang, Biochem 2004 43 4869 4876 10.1021/bi035467b
39. The structure of theinhibitory complex of alloxanthine (1H-pyrazolo[3,4-d]pyrimidine-4,6-diol) with the molybdenum centre of xanthine oxidase from electron-paramagnetic-resonance spectroscopy. TR Hawkes GN George RC Bray, Biochem J 1984 218 961 968 6326752
40. Tight binding inhibitors of xanthine oxidase. R Hille V Massey, Pharm Ther 1981 14 249 263 10.1016/0163-7258(81)90063-2
41. Inhibition of xanthine oxidase and xanthine dehydrogenase by nitric oxide: Nitric oxide converts reduced xanthine-oxidizing enzymes into the desulfo-type inactive form. K Ichimori M Fukahori H Nakazawa K Okamoto T Nishino, J Biol Chem 1999 274 7763 7768 10.1074/jbc.274.12.7763 10075667
42. Enzyme Structure and Mechanism. A Fersht (ed), Cambridge: W.H. Freeman & Company 2 1984
43. Xanthinuria. S Fathallah-Shaykh, WebMD 2005 http://www.emedicine.com/ped/ byname/xanthinuria.htm last updated August 2006
44. Pharmacology of drugs for hyperuricemia: Mechanisms, Kinetics and Interactions. F Pea, Contrib Nephrol 2005 147 35 46 15604604
45. Augmentation of the incorporation of hypoxanthine into nucleic acids by the administration of an inhibitor of xanthine oxidase. R Pomales S Bieber R Friedman GH Hitchings, Biochim Biophys Acta 1963 72 119 120 10.1016/0006- 3002(63)90222-1 13972071
46. Depletion of erythrocyte phosphoribosylpyrophosphate in man. IH Fox JB Wyngaarden WN Kelley, N Engl J Med 1970 283 1177 1182 4319625
47. Pseudofeedback Inhibition of Purine Synthesis by 6-Mercaptopurine Ribonucleotide and Other Purine Analogues. RJ McCollister WR Gilbert Jr DM Ashton JB Wyngaarden, J Biol Chem 1964 239 1560 1563 14189894
48. The conversion of 4-hydroxypyrazolo[3,4-d]pyrimidine (allopurinol) into 4,6-dihroxypyrazolo[3,4-d]pyrimidine (Oxipurinol) in vivo in the absence of xanthine-oxen oxidoreductase. RA Chalmers R Parker HA Simmonds W Snedden RW Watts, Biochem J 1969 112 527 532 5801674
49. Tight binding inhibitors of xanthine oxidase. R Hille V Massey, Pharmacol Ther 1981 14 249 263 10.1016/0163-7258(81)90063-2 6895556
50. Ribonucleosides of allopurinol and oxoallopurinol. Isolation from human urine, enzymatic synthesis, and characterization. TA Krenitsky GB Elion RA Strelitz GH Hitchings, J Biol Chem 1967 242 2675 2682 6028796
51. Differential nature of substrate affinity, kinetics and electron transfer reaction displayed by xanthine and 6-thioxanthine as substrates of milk xanthine oxidase. H Tamta S Kalra GCS Anand AK Mukhopadhyay, J Biol Phys Chem 2005 5 89 99
52. A kinetic study of hypoxanthine oxidation by milk xanthine oxidase. J Escribano F Garcia-Canovas F Garcia-Carmona, Biochem J 1988 254 829 833 3196295
53. Fundamentals of Enzyme Kinetics. London: Portland Press, Cornish-Bowden, A, 3 2004
54. Biochemical Calculations: How to Solve Mathematical Problems in General Biochemistry. IH Segel (ed), Wiley 2 1976
55. Allopurinol: intravenous use for prevention and treatment of hyperuricemia. RV Smalley A Guaspari S Haase-Statz SA Anderson D Cederberg JA Hohneker, J Clin Oncol 2000 18 1758 1763 10764437